alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 32.1

SECTION 1350 CERTIFICATIONS OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

The
certification set forth below is being submitted in connection with this quarterly report on Form 10-Q (the Report) of Logitech International S.A. (the Company) for the purpose of complying with Rule 13a-14(b) or Rule
15d-14(b) of the Securities Exchange Act of 1934 (the Exchange Act) and Section 1350 of Chapter 63 of Title 18 of the United States Code.

Gerald P. Quindlen, the Chief Executive Officer of the Company, and Mark J. Hawkins, the Chief Financial Officer of the Company, each certify that, to the best of his knowledge:



| | (1) | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and
| | --- | --------------------------------------------------------------------------------------------------



| | (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------

November 4, 2008



|                       
|-----------------------
|                       
|/s/ Gerald P. Quindlen 
|Gerald P. Quindlen     
|Chief Executive Officer
|                       
|/s/ Mark J. Hawkins    
|Mark J. Hawkins        
|Chief Financial Officer
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute on Alcohol Abuse and Alcoholism Initial Review Group; Clinical, Treatment and Health Services Research Study Section.                    

*Date:*                         October 13, 2021.                    

*Time:*                         8:00 a.m. to 5:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 6700B Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).                    

*Contact Person:*                         Luis Espinoza, Ph.D., Scientific Review Officer, Extramural Project Review Branch, National Institute on Alcohol Abuse and Alcoholism, 6700B Rockledge Drive, Room 2109, Bethesda, MD 20817, (301) 443-8599,                         *espinozala@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants; 93.701, ARRA Related Biomedical Research and Research Support Awards, National Institutes of Health, HHS)

Dated: July 29, 2021. 

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021-16508 Filed 8-2-21; 8:45 am]

BILLING CODE 4140-01-P
**Exhibit 32.1**

 

 

**Certification of the Chief Executive OfficerPursuant to**

 

**18 U.S.C. Section 1350,**

 

**as Adopted Pursuant to**

 

**Section 906 of the Sarbanes-Oxley Act of2002**

 

 

In connection with theQuarterly Report on Form 10-Q of PRAECIS PHARMACEUTICALS INCORPORATED (the“Company”) for the quarterly period ended September 30, 2003 as filed withthe Securities and Exchange Commission on the date hereof (the “Report”), I,Malcolm L. Gefter, Ph.D., as Chief Executive Officer of the Company, herebycertify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

1.  The Report fully complies with therequirements of Section 13(a) or 15(d) of the Securities Exchange Act of1934; and

 

2.  The information contained in the Reportfairly presents, in all material respects, the financial condition and resultsof operations of the Company.

 

 
|     /s/  Malcolm L. Gefter, Ph.D. |                      |   |
|-------------------------------------------------------|---------------------------|--------|
| Name:                                                 | Malcolm L.  Gefter, Ph.D. |   |
| Title:                                                | Chief  Executive Officer  |   |
| Date:                                                 | November 14,  2003   |   |
|                                                       |                           |        |  |

 

 

A signed original of thiswritten statement required by Section 906, or other documentauthenticating, acknowledging, or otherwise adopting the signature that appearsin typed form within the electronic version of this written statement requiredby Section 906, has been provided to PRAECIS PHARMACEUTICALS INCORPORATEDand will be retained by PRAECIS PHARMACEUTICALS INCORPORATED and furnished tothe Securities and Exchange  Commissionor its staff upon request.

 

This certification accompaniesthe Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 andshall not, except to the extent required by the Sarbanes-Oxley Act of 2002, bedeemed filed by the Company for purposes of Section 18 of the SecuritiesExchange Act of 1934, as amended.

 

----
#### OLSEN v. ROYAL CO.

(Supreme Court, Appellate Division, First Department.

November 15, 1907.)

Action by Anna Olsen against the Royal Company, etc.

No opinion. Motion granted, with $10 costs. Order filed.
# C_2019230EN.01006001.xml

| 8.7.2019 | EN | Official Journal of the European Union | C 230/60 |
| --- | --- | --- | --- |

8.7.2019

EN

Official Journal of the European Union

C 230/60

---

Action brought on 20 May 2019 — SQlab v EUIPO (Innerbarend)

(Case T-307/19)

(2019/C 230/74)

Language of the case: German

Parties

Applicant: SQlab GmbH (Taufkirchen, Germany) (represented by: A. Koelle, lawyer)

Defendant: European Union Intellectual Property Office (EUIPO)

Details of the proceedings before EUIPO

Trade mark at issue: Application for EU word mark Innerbarend — Application for registration No 15 442 635

Contested decision: Decision of the Fourth Board of Appeal of EUIPO of 18 March 2019 in Case R 2180/2018-4

Form of order sought

The applicant claims that the Court should:

| — | annul the contested decision; |
| --- | --- |

—

annul the contested decision;

| — | amend the contested decision to the effect that the action is well founded and the EU trade mark ‘Innerbarend’ is to be registered in Class 12; |
| --- | --- |

—

amend the contested decision to the effect that the action is well founded and the EU trade mark ‘Innerbarend’ is to be registered in Class 12;

| — | order EUIPO to pay the costs. |
| --- | --- |

—

order EUIPO to pay the costs.

Pleas in law

| — | Infringement of Article 7(1)(c) of Regulation (EU) 2017/1001 of the European Parliament and of the Council; |
| --- | --- |

—

Infringement of Article 7(1)(c) of Regulation (EU) 2017/1001 of the European Parliament and of the Council;

| — | Infringement of Article 7(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council. |
| --- | --- |

—

Infringement of Article 7(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council.

---
**CONSENT OF INDEPENDENT ACCOUNTANTS**

 

 

We hereby consent to the incorporation by reference in theRegistration Statement on Forms S-8 (No. 333-106441, 333-98765, 333-62868, 333-38072, 333-33946, 333-91451, 333-88719, 333-85031, 333-53153, 333-52349, 333-52347, 333-52345) and Form S-3 (No. 333- 85628) of Visual Networks, Inc. of our report datedMarch 30, 2004 relating to the financial statements, which appears in the Annual Report to Shareholders, which is incorporated in this Annual Report on Form 10-K. We also consent to the incorporation by reference of our report dated March 30, 2004relating to the financial statement schedule, which appears in this Form 10-K. 

 

 

McLean, Virginia 

March 30, 2004
Exhibit 32.1
 
 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
 AS ADOPTED PURSUANT TO
 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
 In connection with the Quarterly Report on Form 10-Q of Echo Therapeutics, Inc. (the “Company”) for the period ended Marcy 31, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Patrick T. Mooney, M.D., Chief Executive Officer and Chairman of the Board of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002:
 
 (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 /s/ Patrick T. Mooney, M.D.Patrick T. Mooney, M.D.Chief Executive Officer and Chairman of the BoardMay 13, 2011
IN THE SUPREME COURT OF PENNSYLVANIA

MIDDLE DISTRICT

COMMONWEALTH OF PENNSYLVANIA,

Respondent

v.

LAEL J. ALLEYNE,

Petitioner :

:

:

:

:

:

:

:

:

:

: No. 62 MAL 2018

Petition for Allowance of Appeal from

the Order of the Superior Court

ORDER

PER CURIAM

AND NOW , this 13th day of June, 2018

, the Petition for Allowance of Appeal is

DENIED

.
FTC PXA:11

Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 1 of 25 PageID #:9075
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 2 of 25 PageID #:9076
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 3 of 25 PageID #:9077
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 4 of 25 PageID #:9078
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 5 of 25 PageID #:9079
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 6 of 25 PageID #:9080
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 7 of 25 PageID #:9081
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 8 of 25 PageID #:9082
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 9 of 25 PageID #:9083
FTC PXA:12

Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 10 of 25 PageID #:9084
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 11 of 25 PageID #:9085
FTC PXA:13

Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 12 of 25 PageID #:9086
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 13 of 25 PageID #:9087
FTC PXA:14

Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 14 of 25 PageID #:9088
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 15 of 25 PageID #:9089
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 16 of 25 PageID #:9090
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 17 of 25 PageID #:9091
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 18 of 25 PageID #:9092
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 19 of 25 PageID #:9093
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 20 of 25 PageID #:9094
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 21 of 25 PageID #:9095
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 22 of 25 PageID #:9096
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 23 of 25 PageID #:9097
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 24 of 25 PageID #:9098
Case: 1:03-cv-03904 Document #: 626-4 Filed: 04/15/13 Page 25 of 25 PageID #:9099
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. Res. 255 Agreed to Senate (ATS)]

112th CONGRESS
  1st Session
S. RES. 255

   Designating October 8, 2011, as ``National Chess Day'' to enhance 
 awareness and encourage students and adults to engage in a game known 
        to enhance critical thinking and problem-solving skills.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                             August 2, 2011

 Mr. Rockefeller (for himself, Mr. Alexander, and Mr. Levin) submitted 
      the following resolution; which was considered and agreed to

_______________________________________________________________________

                               RESOLUTION

 
   Designating October 8, 2011, as ``National Chess Day'' to enhance 
 awareness and encourage students and adults to engage in a game known 
        to enhance critical thinking and problem-solving skills.

Whereas there are more than 76,000 members of the United States Chess Federation 
        (referred to in this preamble as the ``Federation''), and unknown 
        numbers of additional people in the United States who play the game 
        without joining an official organization;
Whereas approximately \1/2\ of the members of the Federation are scholastic 
        members, and many of the scholastic members join by the age of 10;
Whereas the Federation is very supportive of the scholastic programs and 
        sponsors a Certified Chess Coach program that provides the coaches 
        involved in the scholastic programs training and ensures schools and 
        students can have confidence in the programs;
Whereas many studies have linked chess programs to the improvement of student 
        scores in reading and math, as well as improved self-esteem;
Whereas the Federation offers a school curriculum to educators to help 
        incorporate chess into the school curriculum;
Whereas chess is a powerful cognitive learning tool that can be used to 
        successfully enhance reading and math concepts; and
Whereas chess engages students of all learning styles and strengths and promotes 
        problem-solving and higher-level thinking skills: Now, therefore, be it
    Resolved, That the Senate--
            (1) designates October 8, 2011, as ``National Chess Day''; 
        and
            (2) encourages the people of the United States to observe 
        ``National Chess Day'' with appropriate programs and 
        activities.
                                 <all>
```
f8k112208ex10ii_chinavalves.htm


     

     

    
      


      Exhibit
10.2

       

       

      


      CHINA
VALVES TECHNOLOGY, INC.

      INDEPENDENT
DIRECTOR AGREEMENT WITH WILLIAM HAUS

      


       China Valves Technology,
Inc

       

      Nov 22,
2008

      Dear Mr.
Bill Haus,

       

      Re.: Independent
directorship

       

      We are
writing to confirm your appointment as an independent director of China Valves
Technology, Inc. (the “Company”), which is listed on
the OTCBB under CVVT.OB.

       

      Following
your acceptance, your appointment will be effective as of Dec 01, 2008. You are
entitled to a monthly director’s fee of US$1,000, or its RMB equivalent. Your
monthly fee will be payable monthly. In addition,  you will be granted
10,000 shares of Restricted Common Stock, this Restricted Stock Grant will be
returned to the company should Bill Haus voluntary resign within 18 months. Your
grant date will be Dec 01, 2008. This Restricted Common Stock will be subject to
a lock-up agreement of 30 months in which it cannot be sold or
transferred.  Finally, the company will pay for customary reimbursable
items including one visit per year to the company’s headquarters
facility.

       

      You
hereby agree to maintain the confidentiality of the confidential information and
trade secrets of the Company, including but not limited to, any confidential
information and statistics, business plans, operations, technologies, know-how,
systems and/or the proposed sale, purchase and use of services and products
furnished in oral, visual, written and/or other tangible form and not to
disclose such information to any third party without the prior consent of the
Company.

       

      Please
confirm your acceptance of the appointment as an independent director of the
Company by signing, dating and returning to us the attached copy of this
letter.

       

      Yours
faithfully

       

      /s/ Siping
Fang            

      Fang
Siping

      Chairman
of the Board

       

      I hereby
confirm my acceptance to act as an independent director of the Company upon the
terms contained in this letter.

       

      /s/ William
Haus          


      William
Haus

       

      Date: Nov
22, 2008
----

----

| (1) | The                  Report fully complies with the requirements of Section 13(a) of                  the                  Securities Exchange Act of 1934, as amended;                  and |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | The                  information contained in the Report fairly presents, in all material                  respects, the financial condition and results of operations of                  the                  Registrant. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Dated:                  July 21, 2006 | /s/                  PETER                  KEEFE                                               |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                  | Peter                  Keefe                                                                                                                                                                                                                                                                                                          |
|                                  | Chief                  Executive Officer                                                                                                                                                                                                                                                                                              |

----
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 1 of 30 PageID #:1890
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 2 of 30 PageID #:1891
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 3 of 30 PageID #:1892
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 4 of 30 PageID #:1893
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 5 of 30 PageID #:1894
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 6 of 30 PageID #:1895
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 7 of 30 PageID #:1896
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 8 of 30 PageID #:1897
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 9 of 30 PageID #:1898
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 10 of 30 PageID #:1899
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 11 of 30 PageID #:1900
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 12 of 30 PageID #:1901
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 13 of 30 PageID #:1902
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 14 of 30 PageID #:1903
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 15 of 30 PageID #:1904
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 16 of 30 PageID #:1905
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 17 of 30 PageID #:1906
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 18 of 30 PageID #:1907
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 19 of 30 PageID #:1908
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 20 of 30 PageID #:1909
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 21 of 30 PageID #:1910
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 22 of 30 PageID #:1911
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 23 of 30 PageID #:1912
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 24 of 30 PageID #:1913
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 25 of 30 PageID #:1914
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 26 of 30 PageID #:1915
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 27 of 30 PageID #:1916
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 28 of 30 PageID #:1917
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 29 of 30 PageID #:1918
Case: 1:02-cv-02590 Document #: 329-5 Filed: 11/17/05 Page 30 of 30 PageID #:1919
#### Tracy Y. Bailey, an Infant, by Her Mother and Natural Guardian, Sharon Bailey, Appellant, et al., Plaintiff, v Health Insurance Plan of Greater New York et al., Re*spondents, et al., Defendants.*

*In a medical malpractice ac*tion, the infant plaintiff appeals, as limited by her brief, from so much of (1) a judgment of the Supreme Court, Queens County (Kunzeman, J.), entered September 6, 1984, as, upon a jury verdict, is in favor of respondents, and (2) an order of the same court, dated September 18, 1984, as denied that branch of her motion as sought to set aside the verdict rendered in favor of respondents.

Judgment and order affirmed, insofar as appealed from, with one bill of costs.

Trial Term did not abuse its discretion by limiting of respondents’ expert. An inquiry into the change of opinion in an unrelated case would have created confusion of the issues before the jury *(see, People v Schwartzman,*24 NY2d 241, 245; Richardson, Evidence § 491, at 477 [Prince 10th ed]).

The verdict was not against the weight of the evidence *(see, Cohen v Hallmark Cards,*45 NY2d 493; *Nicastro v Park,*113 AD2d 129).

We have reviewed appellant’s other contentions and find them to be without merit. Gibbons, J. P., Thompson, Brown and Eiber, JJ., concur.